Diabetes mellitus (t Incretins)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Diabetes mellitus (t Incretins).php on line 2
Diabetes mellitus (t Incretins)

LE WE PMID CA

Diabetes mellitus (t Incretins)

11271

Diabetes mellitus (t Inkretine)

Alogliptin

Diabetes mellitus (Beta cell decay)

Diabetes mellitus (t Incretins)

Diabetes mellitus T2DM (Type2)

ERS UFR (Pharmacology)

Exenatide

GLP1 Glucagon like peptide1

GLP2 Glucagon like peptide2

Liraglutide

Liver (Steatohepatosis)

Metformin

Saxagliptin

Sitagliptin

Thiazolidinediones

Vildagliptin

2011 1	The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. [21340625] Diabetologia 54(5): 1098-108 (2011)
2010 2	Liraglutide in the management of type 2 diabetes. [21116334] Drug Des Devel Ther 4(-): 279-90 (2010)
2010 3	Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. [20859539] Vasc Health Risk Manag 6(-): 671-90 (2010)
2011 4	Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. [21415917] Vasc Health Risk Manag 7(-): 49-57 (2011)
2007 5	Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. [17580730] Vasc Health Risk Manag 3(2): 203-10 (2007)
2007 6	Gliptins: a new class of oral hypoglycaemic agent. [17881415] QJM 100(11): 671-7 (2007)
2009 7	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. [19952301] Cleve Clin J Med 76 Suppl 5(-): S28-38 (2009)
2008 8	What role will 'gliptins' play in glycemic control? [18491437] Cleve Clin J Med 75(4): 305-10 (2008)
2010 9	Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. [21106865] Mayo Clin Proc 85(12 Suppl): S27-37 (2010)
2010 10	Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. [21106866] Mayo Clin Proc 85(12 Suppl): S38-49 (2010)
2010 11	A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. [21106868] Mayo Clin Proc 85(12 Suppl): S5-S14 (2010)
2010 12	The evolving place of incretin-based therapies in type 2 diabetes. [20130920] Pediatr Nephrol 25(7): 1207-17 (2010)
2008 13	Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. [18769687] Medscape J Med 10(7): 171 (2008)
2008 14	Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. [18292465] Endocr Rev 29(3): 367-79 (2008)
2007 15	Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. [17622601] JAMA 298(2): 194-206 (2007)
2008 16	Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. [19260377] Acta Biomed 79(3): 184-91 (2008)
2009 17	Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. [19848045] Acta Biomed 80(2): 93-101 (2009)
2010 18	The incretin system and cardiometabolic disease. [20151054] Can J Cardiol 26(2): 87-95 (2010)
2009 19	Incretin-based therapies: viewpoints on the way to consensus. [19875556] Diabetes Care 32 Suppl 2(-): S223-31 (2009)
2008 20	The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. [19036624] Diabetes Metab 34(6 Pt 1): 550-9 (2008)
2008 21	The role of incretins in glucose homeostasis and diabetes treatment. [19074620] Pharmacol Rev 60(4): 470-512 (2008)
2006 22	What are incretins, and how will they influence the management of type 2 diabetes? [16981805] J Manag Care Pharm 12(7 Suppl A): S2-12; quiz S14-6 (2006)
2004 23	Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. [15271645] Am J Physiol Endocrinol Metab 287(2): E199-206 (2004)
2004 24	Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. [15140754] Am J Physiol Endocrinol Metab 286(6): E875-81 (2004)
2004 25	Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. [15140755] Am J Physiol Endocrinol Metab 286(6): E882-90 (2004)
2008 26	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. [18227398] Circulation 117(4): 574-84 (2008)
2004 27	The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. [15561911] Diabetes 53 Suppl 3(-): S197-204 (2004)
2004 28	Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. [15561910] Diabetes 53 Suppl 3(-): S190-6 (2004)
2004 29	Therapeutic strategies based on glucagon-like peptide 1. [15331525] Diabetes 53(9): 2181-9 (2004)
2002 30	The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. [12475787] Diabetes 51 Suppl 3(-): S434-42 (2002)
2007 31	Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. [17337495] Diabetes Care 30(6): 1335-43 (2007)
2007 32	Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. [17337494] Diabetes Care 30(6): 1344-50 (2007)
2006 33	Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. [16443905] Diabetes Care 29(2): 435-49 (2006)
2008 34	DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? [18640591] Diabetes Metab 34 Suppl 2(-): S91-5 (2008)
2008 35	Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. [18640590] Diabetes Metab 34 Suppl 2(-): S78-90 (2008)
2008 36	GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. [18640589] Diabetes Metab 34 Suppl 2(-): S73-7 (2008)
2008 37	Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. [18640588] Diabetes Metab 34 Suppl 2(-): S65-72 (2008)
2005 38	Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. [16142014] Diabetes Metab 31(3 Pt 1): 233-42 (2005)
2003 39	Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. [14645210] Endocrinology 144(12): 5145-8 (2003)
2008 40	Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? [18322302] Eur J Endocrinol 158(6): 773-84 (2008)
2000 41	Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. [11124853] Eur J Endocrinol 143(6): 717-25 (2000)
2008 42	Incretin-based therapies in type 2 diabetes mellitus. [18628530] J Clin Endocrinol Metab 93(10): 3703-16 (2008)
2008 43	The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn? [18258781] J Clin Endocrinol Metab 93(2): 375-7 (2008)
2011 44	The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. [21765869] Therap Adv Gastroenterol 4(4): 249-63 (2011)
2007 45	The pathophysiologic role of incretins. [17724014] J Am Osteopath Assoc 107 Suppl(-): S6-9 (2007)
2007 46	Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus. [17724013] J Am Osteopath Assoc 107 Suppl(-): S10-6 (2007)
2003 47	Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. [14529486] Curr Med Chem 10(22): 2471-83 (2003)
2010 48	Saxagliptin for type 2 diabetes. [21437102] Diabetes Metab Syndr Obes 3(-): 325-35 (2010)
2010 49	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. [21437074] Diabetes Metab Syndr Obes 3(-): 31-41 (2010)
2010 50	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. [21437085] Diabetes Metab Syndr Obes 3(-): 155-63 (2010)
2009 51	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. [21437116] Diabetes Metab Syndr Obes 2(-): 23-30 (2009)
2009 52	Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. [21437121] Diabetes Metab Syndr Obes 2(-): 83-90 (2009)
2009 53	Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. [21437127] Diabetes Metab Syndr Obes 2(-): 135-44 (2009)
2009 54	Alogliptin: a new addition to the class of DPP-4 inhibitors. [21437125] Diabetes Metab Syndr Obes 2(-): 117-26 (2009)
2011 55	Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. [21584276] Exp Diabetes Res 2011(-): 215764 (2011)
2011 56	Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. [21716694] Exp Diabetes Res 2011(-): 376509 (2011)
2011 57	From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. [21747834] Exp Diabetes Res 2011(-): 898913 (2011)
2010 58	Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. [21701614] Drug Healthc Patient Saf 2(-): 7-19 (2010)
2011 59	Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. [21966329] Open Med Chem J 5(Suppl 2): 82-92 (2011)
2011 60	Choosing a gliptin. [22029001] Indian J Endocrinol Metab 15(4): 298-308 (2011)
2009 61	Gliptins: a new class of oral antidiabetic agents. [20376212] Indian J Pharm Sci 71(6): 608-14 (2009)
2009 62	Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. [19801361] J Am Pharm Assoc (2003) 49 Suppl 1(-): S16-29 (2009)
2008 63	The entero-insular axis: implications for human metabolism. [18020966] Clin Chem Lab Med 46(1): 43-56 (2008)
2003 64	Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. [12554744] Mol Endocrinol 17(2): 161-71 (2003)
2010 65	Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. [21143938] BMC Endocr Disord 10(): 20 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Diabetes mellitus (t Incretins).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Diabetes mellitus (t Incretins).php on line 92